West Pharmaceutical
355 hedge funds and large institutions have $8.52B invested in West Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 119 increasing their positions, 109 reducing their positions, and 25 closing their positions.
132% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 25
24% more capital invested
Capital invested by funds: $6.86B → $8.52B (+$1.66B)
10% more funds holding
Funds holding: 324 → 355 (+31)
9% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 109
0.01% less ownership
Funds ownership: 94.11% → 94.09% (-0.01%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
86% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$109M |
| 2 |
WCM Investment Management
Laguna Beach,
California
|
+$39.3M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$37.4M |
| 4 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$24.9M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$24.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$78.3M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$54.6M |
| 3 |
Select Equity Group
New York
|
-$27.7M |
| 4 |
JP Morgan Chase
New York
|
-$22.7M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$21.8M |
WST Hedge Fund Activity: Q3 2018 in Review
355 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2018, worth a combined $8.52B — up 24% from $6.86B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new WST positions and 25 closed out — a net gain of 33 holders — while 119 added to existing stakes and 109 trimmed.
The largest buyer was Federated Hermes, adding an estimated $109M. The largest seller was T. Rowe Price Associates, cutting an estimated $78.3M.
- 355 institutional investors held West Pharmaceutical (WST) as of Q3 2018, up from 324 in Q2 2018.
- Funds reported $8.52B of West Pharmaceutical stock for Q3 2018, up 24% quarter-over-quarter.
- 58 funds opened new West Pharmaceutical positions in Q3 2018 and 25 closed out, a net change of +33 holders.
- The largest West Pharmaceutical buyer in Q3 2018 was Federated Hermes, an estimated $109M added.
- The largest West Pharmaceutical seller in Q3 2018 was T. Rowe Price Associates, an estimated $78.3M sold.
Based on aggregated 13F filings for Q3 2018.